FDA staffers raise concerns about Sanofi's iGlarLixi

Staffers at the US Food and Drug Administration have questioned the efficacy of French drug company Sanofi’s (Euronext: SAN) experimental diabetes drug iGlarLixi.

In a briefing document ahead of an FDA advisory committee on May 25, reviewers raised concerns about the usefulness of putting patients on two medications when one may be enough.

They also questioned the results of the clinical trials which were designed to show that the therapy is superior to insulin alone.